Novartis Ag (NVS) Cash from Restructuring (2018)

Novartis Ag (NVS) posted Cash from Restructuring of -$16.0 million for Q4 2018, up 51.52% sequentially from -$33.0 million in Q3 2018.

Novartis Ag (NVS) Cash from Restructuring (2018) Analysis & Trends

Novartis Ag (NVS) has 1 years of Cash from Restructuring data on file, last reported at -$16.0 million in Q4 2018.

Quarterly Cash from Restructuring changed N/A year-over-year to -$16.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$57.0 million (changed N/A YoY) and the FY2018 annual result came in at -$57.0 million, changed N/A from the prior year.
Cash from Restructuring grew to -$16.0 million in Q4 2018 per NVS's latest filing, from -$33.0 million in the prior quarter.
The five-year high for Cash from Restructuring was -$8.0 million in Q2 2018, with the low at -$33.0 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn

Download Data